- Home
- AUPH
as of 01-22-2026 3:52pm EST
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
| Founded: | 1993 | Country: | Canada |
| Employees: | N/A | City: | EDMONTON |
| Market Cap: | 1.6B | IPO Year: | 1999 |
| Target Price: | $17.25 | AVG Volume (30 days): | 939.1K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.55 - $16.54 | Next Earning Date: | 02-26-2026 |
| Revenue: | $265,808,000 | Revenue Growth: | 20.62% |
| Revenue Growth (this year): | 21.76% | Revenue Growth (next year): | 16.45% |
Compare AUPH vs Leading Stocks
See how AUPH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AUPH Aurinia Pharmaceuticals Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.